DUBLIN--(BUSINESS WIRE)--The "Vaccines Market by Indication (Influenza, Rotavirus, DTP Vaccines), Route of Administration (Intramuscular, Subcutaneous, Oral), Type/Antigen (Conjugate Vaccine, Live Attenuated Vaccine), Valence (Multivalent, Monovalent Vaccines) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
The global vaccines market is expected to grow at a CAGR of 5.2% from 2019 to 2027 to reach $62.2 billion by 2027.
The growth in the global vaccines market is mainly attributed to the high prevalence of various diseases, increasing government initiatives towards immunization, technological advancements in the vaccine industry, and a strong pipeline for vaccines. In addition, increasing epidemic potentials, growing focus on therapeutic vaccines, and emerging markets will further provide significant opportunities for the various stakeholders in this market. However, longer timelines and high cost for vaccines development are likely to hinder the market growth.
On the basis of indication, the pneumococcal disease segment commanded the largest share of the overall vaccines market in 2019. The large share of this segment is mainly attributed to the factors such as rising incidence of pneumococcal diseases like pneumonia, meningitis, febrile bacteraemia, otitis media, and sinusitis; development of quality vaccines such as PPSV23; and various initiatives by the government organizations and private sectors to prevent and control outbreak of pneumococcal diseases.
On the basis of valence, multivalent vaccines segment accounted for the largest share of the overall vaccines market in 2019 and is poised to grow at a faster CAGR during the forecast period. New product launches and focus of key players on multivalent vaccine' research & development are the major factors contributing to the largest share and fastest CAGR of multivalent vaccines market segment.
On the basis of antigen, subunit and conjugate vaccines segment accounted for the largest share of this market in 2019 due to long term immunity and low-risk rate associated with the subunit vaccines along with the increasing demand for immunization.
Key Topics Covered:
2 Research Methodology
3. Executive Summary
4. Market insights
4.1. Market Overview
4.2.1. Strong Vaccines Pipeline
4.2.2. Rising Adoption of Vaccination
4.2.3. Increasing Government Focus on Immunization Programs
4.2.4. Technological Progress in Vaccine Administration
4.3.1. High Cost Associated with Vaccine Development
4.3.2. Longer Timelines for Vaccine Manufacturing
4.4.1. Increasing Epidemic Potentials
4.4.2. Growing Focus on Therapeutic Vaccines
4.4.3. Growth Prospects in Emerging Markets
4.4.4. Increasing Use of Adjuvants in Vaccines
4.5.1. Product Recalls
4.5.2. Inadequate Access to Vaccines
5. Industry Analysis
5.1. Regulatory Analysis
5.2. Pipeline Analysis
5.3. Unmet Needs Analysis
5.4. Pricing Analysis, by Region
6. Global Vaccines Market, by Indication
6.2. Pneumococcal Disease
6.4. Human Papilloma Virus (HPV)
6.6. Meningococcal Disease
6.9. Poliomyelitis (Polio)
6.11. Other Indications
7. Global Vaccines Market, by Route of Administration
7.2. Intramuscular (IM)
7.3. Subcutaneous (SC)
7.5. Other (Routes of Administration)
8. Global Vaccines Market, by Type/Antigen
8.2. Subunit & Conjugate Vaccines
8.3. Inactivated Vaccines
8.4. Live Attenuated Vaccines
8.5. Toxoid Vaccines
8.6. Combination Vaccines
9. Global Vaccines Market, by Valence
9.2. Multivalent Vaccines
9.3. Monovalent Vaccines
10. Global Vaccines Market, by Geography
10.2. North America
10.3.6. Rest of Europe
10.4. Asia Pacific
10.4.4. Rest of Asia Pacific
10.5. Latin America
10.6. Middle East & Africa
11. Competitive Landscape
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis
11.4.1. Market Share Analysis, by Company
11.4.2. Market Share Analysis, by Product
12. Company Profiles
12.1.1. Business Overview
12.1.2. Financial Overview
12.1.3. Product Portfolio
12.1.4. Pipeline Products
12.1.5. Strategic Developments
12.2. Merck & Co., Inc.
12.3. GlaxoSmithKline Plc.
12.4. Pfizer, Inc.
12.5. Johnson & Johnson
12.6. Daiichi Sankyo Co., Ltd.
12.7. Takeda Pharmaceutical Company Limited
12.8. CSL Limited
12.9. Emergent BioSolutions Inc.
For more information about this report visit https://www.researchandmarkets.com/r/kpbu7e